PS1561 RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS

Authors :: I. Khouri
R. Mehta
M. Qazilbash
Celina Ledesma
Alison M. Gulbis
L. J. Nastoupil
Stefan O. Ciurea
B. Oran
David Marin
F. Samaniego
F. H. Hagemeister
Ken H. Young
R. Champlin
Qaiser Bashir
U. Popat
Gheath Alatrash
L.J. Medeiros
Amin M. Alousi
Denái R. Milton
Amanda Olson
L. Fayad
G. Rondon
J. Im
J. Molldrem
Source :: HemaSphere. 3:720
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
medicine.medical_specialty
Median follow-up
business.industry
Internal medicine
Follicular lymphoma
Medicine
Rituximab
Hematology
Stem cell
business
medicine.disease
medicine.drug

Tools